Why and how do we need comprehensive international clinical epidemiology of ARDS?

被引：2

|

作者：

Tognoni, Gianni ^{[1
]}

Vivona, Luigi ^{[2
]}

Pesenti, Antonio ^{[1
,2
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anesthesia & Crit Care, Milan, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

INTENSIVE CARE MEDICINE | 2021年 / 47卷 / 09期

关键词：

RESPIRATORY-DISTRESS-SYNDROME; MORTALITY;

D O I：

10.1007/s00134-021-06469-0

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

收藏

页码：1014 / 1016

页数：3

相关论文

共 34 条

[31] How can we explain the gap between randomised studies and 'real life' practice in postoperative transfusion triggers? Do we need to change recommended thresholds for transfusion?
Rosencher, Nadia
Ozier, Yves
Souied, Francois
Lienhart, Andre
Samama, Charles-Marc
EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2012, 29 (10) : 460 - 461
[32] Cinacalcet - Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?
Smrzova, Jana
Urbanek, Tomas
KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (05) : 333 - 342
[33] Extracellular vesicles in the diagnosis and treatment of cardiovascular disease. What's behind? What do we need to implement them into clinical practice?
Nowicka, Grazyna
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2024, 172
[34] Endpoints in PAH clinical trials in the era of combination therapy: How do we decide whether something is working without going bankrupt?
McGlinchey, Neil
Peacock, Andrew J.
DRUG DISCOVERY TODAY, 2014, 19 (08) : 1236 - 1240

← 1 2 3 4 →